A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2002
12/10/2002	US6492396 Substituted thioacetamides
12/10/2002	US6492394 Procollagen c-proteinase inhibitors; treating fibrotic diseases
12/10/2002	US6492390 Treating cyclooxygenase-2 mediated disorders.
12/10/2002	US6492379 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
12/10/2002	US6492376 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
12/10/2002	US6492372 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
12/10/2002	US6492371 Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of Parkinson's Disease
12/10/2002	US6492368 Benzamidine derivatives as factor XA inhibitors
12/10/2002	US6492366 Cyano-indole serotonin-reuptake inhibitor compound
12/10/2002	US6492364 Triazolo and derivatives as chemokine inhibitors
12/10/2002	US6492358 For treatment of sexual disorders, male erectile dysfunction
12/10/2002	US6492356 Acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists
12/10/2002	US6492353 1,3-dihydroxy-20,20-cycloalkyl-vitamin D3analogs
12/10/2002	US6492347 Treatment and/or prophylaxis of infection caused by protozoan parasite by administering compound to inhibit purine nucleoside hydrolase, purine nucleoside phosphorylase, and/or purine phosphoribosyl transferase
12/10/2002	US6492342 Hygromycin A prodrugs
12/10/2002	US6492333 Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
12/10/2002	US6492331 NL8 tie ligands homologues
12/10/2002	US6492327 Isolation of purified TGF- β1 and TGF -β2 from bone tissue
12/10/2002	US6492325 Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
12/10/2002	US6492157 Methods are provided for the treatment of conditions associated with cells proliferation, cells differentiation and cell survival. in particular, the dual-specificity phosphatase dsp-9, and polypeptide variants thereof that
12/10/2002	US6492129 Fragments comprising the n-terminal region of connective tissue growth factor (ctgf); screening for inhibitors or stimulators of ctgf
12/10/2002	US6491915 Anti-CCR2 antibodies and methods of use therefor
12/10/2002	US6491903 Particles comprising amphiphilic copolymers
12/10/2002	CA2230445C Fibrinogen receptor antagonists and medicinal preparations containing the same as the active ingredient
12/10/2002	CA2228752C (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate
12/10/2002	CA2209695C Use of a polyholoside in a composition to promote desquamation and the composition containing it
12/10/2002	CA2208792C Substituted indazole derivatives
12/10/2002	CA2202924C Use of at least one lipoxygenase inhibitor and at least one cyclo-oxygenase inhibitor to alter the growth of hair
12/10/2002	CA2092431C 3,9-diazabicyclo (3.3.1) nonan-7-yl derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
12/10/2002	CA1341408C Method for treating and preventing loss of bone mass
12/09/2002	WO2001096366A2 Dipeptide inhibitors for the blood-clotting factor xa
12/09/2002	CA2412181A1 Dipeptide inhibitors for the blood-clotting factor xa
12/08/2002	WO2003000892A1 Gene encoding b protein
12/08/2002	CA2398093A1 Gene encoding protein b
12/06/2002	WO2002000605A1 Novel dicarboxylic acid derivatives
12/06/2002	CA2411059A1 Novel dicarboxylic acid derivatives
12/05/2002	WO2002097120A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002	WO2002097094A1 Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis
12/05/2002	WO2002097053A2 Small molecule antagonists of bcl2 family proteins
12/05/2002	WO2002097043A2 Wnv core protein/capsid interacting protein and uses of the same
12/05/2002	WO2002097042A2 Chimeric proteins for cell targeting and apoptosis induction and methods of using the same
12/05/2002	WO2002097030A2 Peptides derived from neural thread proteins and their medical use
12/05/2002	WO2002096952A2 Conjugate of a transport protein and a protein for modulation of notch signalling
12/05/2002	WO2002096939A2 Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
12/05/2002	WO2002096933A1 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives
12/05/2002	WO2002096927A2 Ribozyme based treatment of female reproductive diseases
12/05/2002	WO2002096926A1 Modulators of pharmacological agents
12/05/2002	WO2002096921A1 Novel glucose derivative inducing apoptosis, process for producing the same, and use thereof as medicine
12/05/2002	WO2002096913A1 Substituted di(hydroxy/alkoxy)silicon phthalocyanines and their uses
12/05/2002	WO2002096911A1 Novel heteroaryl-diazabicyclo-alkanes as cns-modulators
12/05/2002	WO2002096910A1 Cytotoxins, prodrugs, linkers and stabilizers useful therefor
12/05/2002	WO2002096909A1 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
12/05/2002	WO2002096904A1 Novel heterocyclic derivatives and medicinal use thereof
12/05/2002	WO2002096903A2 Chemical derivatives and the use thereof as an anti-telomerase agent
12/05/2002	WO2002096896A1 Biologically active methylene blue derivatives
12/05/2002	WO2002096892A1 Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
12/05/2002	WO2002096888A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments
12/05/2002	WO2002096887A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
12/05/2002	WO2002096886A1 Pyrimidine derivatives
12/05/2002	WO2002096885A1 Pyrimidine derivatives useful as selective cox-2 inhibitors
12/05/2002	WO2002096883A1 Tricyclic compounds useful as angiotensin ii agonists
12/05/2002	WO2002096879A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
12/05/2002	WO2002096877A1 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
12/05/2002	WO2002096867A2 Inhibitors of protein kinase for the treatment of disease
12/05/2002	WO2002096866A2 Thiolalkyl benzoic acid derivatives
12/05/2002	WO2002096864A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
12/05/2002	WO2002096858A1 Cinnamide derivatives as kcnq potassium channel modulators
12/05/2002	WO2002096855A2 Anticholinergic compounds and methods of use
12/05/2002	WO2002096516A1 Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease
12/05/2002	WO2002096467A2 Pharmaceutical use for secreted bacterial effector proteins
12/05/2002	WO2002096456A1 Use of il-18 inhibitors for treating or preventing cns injuries
12/05/2002	WO2002096453A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin
12/05/2002	WO2002096449A1 Carbohydrate modifying agent and drinks containing the modifying agent
12/05/2002	WO2002096436A1 The use of a compound with a negatively charged domain of radicals for the treatment of restenosis
12/05/2002	WO2002096435A2 Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
12/05/2002	WO2002096433A1 Methods for treating delirium using glucocorticoid receptor-specific antagonists
12/05/2002	WO2002096427A1 Pyrimidine derivatives as selective inhibitors of cox-2
12/05/2002	WO2002096426A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002	WO2002096424A1 Hetereocyclic beta-aminoacids and their use as anti-epileptogenic agents
12/05/2002	WO2002096423A2 Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
12/05/2002	WO2002096420A2 Method for treating nerve injury caused by surgery
12/05/2002	WO2002096418A1 Pirenzepine ophthalmic gel
12/05/2002	WO2002096414A1 Medicament containing an effector of the glutathione metabolism together with alpha-lipoic acid for use in kidney replacement therapy
12/05/2002	WO2002096402A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a biguanide drug
12/05/2002	WO2002096398A2 Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for treating diabetes mellitus
12/05/2002	WO2002096363A2 Method for treating fibrotic diseases or other indications
12/05/2002	WO2002096360A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002	WO2002096358A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002	WO2002096357A2 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
12/05/2002	WO2002096354A2 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin
12/05/2002	WO2002096349A2 Vaccination against the feline immunodeficiency virus
12/05/2002	WO2002096348A2 Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
12/05/2002	WO2002096218A2 Combination of lipoic acids, carnitines, and creatines in food and pharmaceuticals
12/05/2002	WO2002096216A1 A method of improving the growth performance of an animal
12/05/2002	WO2002081415A3 Method for inhibiting metap2
12/05/2002	WO2002080854A3 Compositions and methods for the prevention and treatment of human prostate cancer
12/05/2002	WO2002074036A3 Substituted benzopyranones as telomerase inhibitors
12/05/2002	WO2002070557A3 Nuclear hormone receptor ligand binding domain
12/05/2002	WO2002066450A3 Anthrone derivatives and their use as ink inhibitors
12/05/2002	WO2002064547A3 Isophthalic acid derivatives as matrix metalloproteinase inhibitors

1 ... 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 ... 1564